3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Neoplasms
1
Interventions
Everolimus
5
Sunitinib
4
lutetium Lu 177 dotatate
2
PM 01183
2
Octreotide
2
Doxorubicin
2
trifluridine tipiracil drug combination
1
telotristat ethyl
1
repotrectinib
1
pralsetinib
1
pegfilgrastim
1
pasireotide
1
motesanib diphosphate
1
epothilone B
1
dactolisib
1
copper dotatate CU-64
1
batifiban
1
avelumab
1
alectinib
1
Temozolomide
1
TKM-080301
1
Surveys and Questionnaires
1
SNX-5422
1
Referral and Consultation
1
Radiomics
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Molecular Diagnostic Techniques
1
Lutetium-177
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
AMG 757
×
NET
×
Clear all
NCT06502977
2026-04-15
DeLLphi-307
Amgen
Phase 2
Active not recruiting
32 enrolled
9 charts